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Activated gelatinase A is reportedly associated with tumor spread. We identified novel
matrix metalloproteinases that localize on the cell surface and mediate the activation of
progelatinase A. Thus, these progelatinase A activators were named membrane-type
matrix metalloproteinase-1 and -2 (MT-MMP-1 and -2, respectively). MT-MMP-1 is
overexpressed in malignant tumor tissues, including lung and stomach carcinomas that
contain activated gelatinase A. This suggests that MT-MMP-1 is associated with the
activation of progelatinase A in these tumor tissues. The expression of MT-MMP-1 also
induced binding of gelatinase A to the cell surface by functioning as a receptor. The cell
surface localization of proteinases has advantages over pericellular proteolysis. MT-MMP -
1 and its family may play a central role in the cell surface localization and activation of
progelatinase A and via this mechanism, tumor cell use exogenous progelatinase A to
mediate the proteolysis associated with invasion and metastasis.
Key words: gelatinase A, gelatinase A activator, matrix metalloproteinase, MT-MMP,
tumor metastasis.
A major characteristic of malignant tumor cells is their
ability to invade and form metastatic foci at distant sites in
the body. The high frequency at which matrix metallopro-
teinase (MMP) transcripts or proteins is detected in inva-
sive tumor cells and tissues suggests that these enzymes
are closely associated with tumor invasion and metastasis
(1, 2). The degradation of the extracellular matrix should
be an essential step to allow the spread of the tumor cells.
Extracellular matrix has dynamic roles not only in
supporting tissue structures but also in regulating cellular
functions. For example, cell proliferation, differentiation,
adhesion, and motility are tightly controlled by surround-
ing environment extracellular matrix. A number of studies
have provided evidence for the involvement of MMPs and
their inhibitors in developmentally regulated processes.
These include ovulation (3), embryogenic growth and
differentiation (4), and the development of organs (5).
Thus, the expression of MMPs involved in the degradation
of components of extracellular matrix must be tightly
regulated and the overexpression of MMPs should be
associated with various pathological events (6, 7).
The expression of MMP function is regulated mainly by
3 processes: transcription, activation of latent MMP, and
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inhibition by tissue inhibitor of MMPs (TIMP) (8). In
addition to the overexpression of various MMPs in tumors,
the close correlation between gelatinase A activation and
metastatic progression in various tumors suggests that
gelatinase A activator is a key enzyme triggering tumor
spread (9-12). In this review we focus on the membrane-
type MMP associated with activation of progelatinase A.
Modular structure of MMPs
The MMP gene family encodes 11 metal-dependent
endopeptidases with activity against most, if not all
extracellular matrix macromolecules. The enzymes have a
similar structure composed of the five modular domains
(Fig. 1A). The hydrophobic signal sequence is followed by
a propeptide that is important to maintain the latency of the
enzyme and which is cleaved when the enzyme is activated.
The catalytic domain contains the two Zn2+-binding sites
that are essential for the catalytic function. The proline-
rich hinge region marks the transition to the ~200 residue
hemopexin- or vitronectin-like COOH-terminal domain
that appears to play a role in encoding substrate specificity.
Matrilysin/PUMP-1 does not possess this last domain and
therefore is considerably smaller than the other members
of the family. The two gelatinases have an insertion which
has sequence similarity to the collagen-binding domains of
fibronectin in the catalytic domain (13, 14). The fibronectin
domain is involved in the substrate-binding properties of
the molecules.
Activation mechanism of MMP
MMP is secreted in a proenzyme form which is en-
zymatically inactive. Van Wart's group has proposed a
cysteine switch model for the mechanism of maintaining
Vol. 119, No. 2, 1996 209
210 H. Sato and M. Seiki
A







Fig. 1. Scheme of the domain structures and cystelne switch
mechanism for MMP activation. A: The domain structure. Signal,
signal peptides; Pro, the pro-peptide domain that contains PRC-
GVPD, the most conserved sequence in the pro-peptide domain and is
necessary to mask the active site of enzymes; Catalytic, core domain
essential for enzymatic activity; Zn1+, Zn2+-binding site; Fibronectin,
a fibronectin-like domain of two gelatinases (gelatinases A and B);
Hinge, proline-rich sequence potentially functioning as a hinge
region; Hemopexin, hemopexin-like repeat. B: Cysteine switch
mechanism. Proteolytic enzymes cleave the propeptide, ahead of the
cysteine to generate intermediate forms. Alternatively, reagents that
react with sulfydryl groups, such as organomercurials (e.g. amino-
phenyl-mercuric acetate, APMA), will modify the cysteine. In a
second step, these intermediate forms can be autoproteolytically
cleaved to remove the propeptide and confer permanent activity.
the latency that is shown in Fig. IB {15). The "Pro" domain
of the latent molecule is folded around so that the cysteine
residue in the conserved PRCGVPD region can form a
complex with the zinc molecule (16). Proteinases (trypsin,
plasmin, chymotrypsin, neutrophil elastase, and plasma
kalikrein) that attack a short basic sequence exposed on the
surface of the molecule are thought to trigger the activation
process of proMMPs in vivo (17). This initial cleavage
causes a conformation change in the molecule that disrupts
the cysteine-Zn2+ interaction and frees the Zn2+ to partici-
pate in the proteolytic cleavage. The mechanism is thus
called "cysteine switch mechanism." The enzyme can then
attack the peptide sequence downstream of the PRCGVPD
in an autolytic manner and cleave it (by both intra- and
intermolecular mechanisms). An alternative activation of
the enzyme with mercurial compounds such as amino-
phenyl-mercuric acetate (APMA) causes chemical modi-
fication of the cysteine and generates free zinc at the
catalytic center by the cysteine switch mechanism.
Gelatinase A is unique among MMPs in that it does not
possess sequences susceptible to proteolytic activation by
the above serine proteinases. The mechanism of progelatin-
ase A activation has been attracted attention of many
tumor biologists, because a close association between the
expression of activated gelatinase A and tumor spread has
been found in various types of tumors (10, 11).
Identification of membrane-type MMP
Activated gelatinase A is released in vitro from fibrosar-
coma HT1080, breast tumor MDA-MB-321, and normal
fibroblast cells stimulated with TPA or concanavalin A (18-
21). The activation activity resides in the plasma mem-
brane fraction and it is sensitive to EDTA and TIMP-2
which are inhibitors of MMP, thus suggesting that the
activator might be a membrane-bound MMP.
All the known MMPs are in a soluble form and none of
them is the membrane-type. The complexity of extracel-
lular matrix components suggests that more MMPs are
involved in the efficient turnover of extracellular matrix
during tissue remodeling. However, conventional biochem-
ical approaches are no longer useful for identifying un-
known enzymes. Polymerase chain reaction (PCR) using a
set ui uegeQcrate primers for conserved smino acid se-
quences is a powerful means with which to identify new
members of a gene family. Amino acid sequences for the
cysteine switch (PRCGVPD) and binding sites for zinc
molecule are highly conserved among all known MMPs.
Reverse-transcription PCR amplification of MMP gene
fragments with degenerate primers for these sequences
using mRNA from various sources as a template has
amplified not only known MMP genes but also unique
fragments homologous to MMP (22). One of these was
derived from human placenta and the other from melanoma
tissue. Two cDNAs have been isolated from a human
placenta cDNA library using these fragments as probes
(22-24). Long open reading frames encoding 582 and 604
amino acids (aa) have been identified; both of these were
aligned with known MMP family members but they were
most closely related to each other (Fig. 2). While these
proteins have a common MMP domain structure, they have
three unique insertions. First there is an insertion of 11 aa
between the pro-peptide and the catalytic enzyme domains.
Stromelysin-3/MMP-11 has a similar insertion at the same
position (25). The conserved RXKR sequences precede the
potential processing sites of these two MMPs. The peptide
bond following RXKR is the processing site of many
secretory proteins by the eukaryotic KEX2 family of
endopeptidase (26). Stromelysin-3 is activated by furin,
one of intracellular KEX2 family endopeptidases (27). The
MT-MMPs have a second insertion of 8 aa in the catalytic
enzyme domain which is not present in other MMPs. The
J. Biochem.
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Fig. 2. (continued on next page)
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Fig. 2 Alignment of MMP aa sequences. The reported human MMPs are
listed and aligned with the deduced MT-MMP-1 and MT-MMP-2 proteins.
Specific insertions characteristic to MT-MMPs are indicated by the upward
arrows (IS-1 to IS-3)
3T3
(kDa) (kDa)
Fig. 3. Expression of MT-MMP. A: Cell surface localization of
MT-MMP expressed m COS-1 cells. COS-1 cells transfected with
control or MT-MMP-1 expression plasmid were stained by an im-
munofluorescent antibody staining method using a monoclonal anti-
body against MT-MMP-1. B: Processing of progelatinase A by the
expression of MT-MMP-1 Culture supematants from HT-1080 or
NEH3T3 cells transfected with control or MT-MMP-1 expression
plasmid or treated with concanavalin A were analyzed by gelatin
zymography.
third insertion at the C terminus contains a hydrophobic
amino acid stretch which can pass through the plasma
membrane and act as a potential transmembrane domain.
Therefore, they were named membrane-type MMP (MT-
MMP-1 and MT-MMP-2, respectively) (23, 24). MT-MMP
proteins were localized in the membrane by the immuno-
fluorescent staining of transfected cells with monoclonal
antibodies raised against MT-MMP-1 and MT-MMP-2
peptides (Fig. 3A). These antibodies recognized 63 and 64
kDa proteins for MT-MMP-1 and MT-MMP-2, respective-
ly.
Activation of progelatinase A by MT-MMP expression
The expression of MT-MMP on the cell surface fits the
requirements for an activator for progelatinase A. The
expression of MT-MMP-1 in cells secreting 68 kDa progela-
tinase A and 92 kDa progelatinase B converted only
progelatinase A to the 62 kDa fully active form through the
64 kDa intermediate as demonstrated by gelatin zymogra-
phy (Fig. 3B) (24). MT-MMP-2 expression also induced
progelatinase A activation (23). The MT-MMP-1 mRNA
transcript and protein were expressed in MDA-MB-231
cells stimulated with concanavalin A and HT1080 cells
exposed to TPA, indicating that the gelatinase A activator
in these cells is MT-MMP-1 (28, 29).
Expression of MT-MMP genes in human tissues
MT-MMP-1 and MT-MMP-2 mRNA transcripts (4.5 and
12 kb, respectively) are expressed in various tissues, but
they are distributed quite differently (22, 23). MT-MMP-1
mRNA expression is predominant in the lungs, kidneys,
and placenta where extracellular matrix remodeling is
relatively active, and lowest in the brain. In contrast,
MT-MMP-2 mRNA expression is high in the heart, brain,
and placenta, and is undetectable in the lungs, kidneys,
liver, spleen, and muscle.
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Fig. 4. Expression of MT-MMP-1 stimulates the invasion of
cells in vitro. NIH3T3 and HT1080 cells were transfected with
MT-MMP-1 (MT-MMP) or control plasmids, then the invasion of the
reconstituted basement membrane in the presence (Matngel +
rTIMP-2) or absence of 10^g/ml recombinant TIMP-2 (Matngel)
was assayed Motility was analyzed on uncoated filters (Uncoated).
Elevated expression of MT-MMP-1 in tumor tissues
A significant statistical association between the expres-
sion level of activated gelatinase A in tumor tissue and
tumor spread has been reported. Therefore, attempts have
been made to identify the gelatinase A activator in tumor
tissues (24, 30, 31). MT-MMP-1 expression is elevated in
various tumor tissues including lung, gastric, colon, and
breast cancers, in which activated gelatinase A is expres-
sed. Detailed statistic analyses have demonstrated a close
correlation between MT-MMP-1 expression and gelatinase
A activation in lung carcinoma, indicating that MT-MMP-1
is involved in the activation of gelatinase A in tumor tissue.
Although the MT-MMP-2 cDNA fragment has been ob-
tained from melanoma tissue, elevated expression of
MT-MMP-2 is not often observed in tumor tissues.
According to immunohistochemical studies of gastric
carcinomas, MT-MMP-1 is predominantly localized in and
on carcinoma cells {30). On the other hand, gelatinase A is
immunolocalized only on the cell membranes of carcinoma
cells. Almost all gelatinase A-positive tumors expressed
MT-MMP-1 in the cells as well. In most of these, fibroblasts
and vascular endothelial cells in the advanced carcinoma
tissue were also immunostained for MT-MMP and gela-
tinase A and the staining was weak or negative in the
normal tissue remote from the carcinoma. It seems that
MT-MMP-1 is expressed in the stromal cells in patho-
physiological conditions, where the extracellular matrix
macromolecules are undergoing rapid remodeling. Colocal-
ization of gelatinase A with MT-MMP-1 on the tumor cell
membrane raised the question as to how gelatinase A, of
which the mENA transcript was detected in stromal cells
around tumor cells, localizes on the tumor cell membrane.
This is consistent with the in vitro finding that activated
gelatinase A is enriched in the plasma membrane of cancer
cells. Although the specific binding of gelatinase A to the
surface of tumor and normal fibroblast cells has been
described, a membrane protein that functions as a gela-
TIMP-2
Fig 5. Scheme illustration of the binding and activation of
progelatinase A by MT-MMP and its inhibition by TIMP-2 on
the cell surface.
tinase A receptor has not been identified.
MT-MMP-1 also functions as a receptor of gelatinase A
The fact that activated gelatinase A is enriched in the
plasma membrane of cancer cells in which MT-MMP
localizes, suggests that MT-MMP is involved not only in the
activation but also in the binding of gelatinase A {32, 33).
The specific binding of gelatinase A to the cells expressing
MT-MMP was demonstrated by a study using 125I-labeled
progelatinase A that was processed to the intermediate
form (Sato, H., Takino, T., Kinoshita, T., Imai, K., Okada,
Y., Stetler-Stevenson, W.G., and Seiki, M., manuscript
submitted). Complex formation between MT-MMP and
gelatinase A was demonstrated by immunoprecipitation
using monoclonal antibodies against MT-MMP and gela-
tinase A. These results indicated that MT-MMP serves not
only as an activator but a receptor of gelatinase A. Process-
ing from the intermediate to fully active form was depen-
dent on the gelatinase A concentration. Unlike the wild-
type progelatinase A, a mutant defective in catalytic
function was processed only to the intermediate form by
co-expression with MT-MMP. Thus, the processing of
progelatinase A to intermediate form is catalyzed by the
function of MT-MMP and the binding with MT-MMP on the
cell surface concentrates the intermediate form locally to
allow autoproteolytic processing to the fully active form.
Blocking of gelatinase A binding by TIMP-2
TIMP-2 but not TIMP-1 binds to the surface of normal
fibroblast cells and inhibits the activation of progelatinase
A by these cells (34; Sato, H., Takino, T., Kinoshita, T.,
Imai, K., Okada, Y., Stetler-Stevenson, W.G., and Seiki,
M., manuscript submitted). This suggests direct interac-
tion between TTMP-2 and MT-MMP. Indeed, TIMP-2
bound to cells expressing MT-MMP and interfered with the
binding and activation of progelatinase A. Immunoprecipi-
tation has shown that TIMP-2 forms a complex with
MT-MMP. Therefore, TIMP-2 is thought to competitively
inhibit binding of gelatinase A to MT-MMP.
Expression of MT-MMP stimulates the invasion of
cells
As gelatinase A degrades various extracellular matrix
macromolecules, including type IV collagen and laminin,
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we determined whether or not progelatinase A activated by
MT-MMP expression enhances the invasiveness of cells
producing progelatinase A. We found that MT-MMP
expression in HT-1080 and NIH3T3 cells more than
doubled the number of invasive cells compared with con-
trols when analysed using a modified Boyden Chamber (Fig.
4) {24). The invasion was sensitive to TIMP-2, which
inhibits binding and activation of gelatinase A by MT-MMP
and also the proteolytic activity of activated gelatinase A.
Implications
Tumor spread reportedly correlates with increased
levels of activated gelatinase A (10, 11). This activation
occurs in association with the plasma membrane and
activated gelatinase A binds specifically to the tumor cell
surface, although the molecular features of these interac-
tions remain to be elucidated. MT-MMP-1 fulfills the
criteria for a plasma membrane associated activator and
receptor of gelatinase A. Via this mechanism, MT-MMP
localizes matrix digestion to the vicinity of the tumor cell
surface (Fig. 5). The cell surface binding of gelatinase A not
only promotes enzyme activation but also regulates enzyme
activity by increasing the rate of substrate cleavage (35).
The cell surface localization of proteinases is a common
cellular strategy for regulating pericellular proteolysis, as
exemplified by urinary-type PA (uPA), the activity of
which is localized predominantly on the cell surface via
binding to the specific uPA receptor (36). Co-expression of
MT-MMP and gelatinase A in osteoblasts during mouse
embryonic development and the efficient activation of
progelatinase A in the tissue indicate that the MT-MMP-
gelatinase A system plays an important role in tissue
remodeling during organogenesis (Kinoh, A., Sato, H.,
Tsunezuka, Y., Okada, Y., Kawashima, A., and Seiki, M.,
manuscript submitted). Thus, MT-MMP and its family
play a central role in the activation and cell surface localiza-
tion of gelatinase A not only in tumor invasion and
metastasis but also during normal development. Identifica-
tion of the proteinase that triggers the proteolytic cascade
of human cancers should be valuable both as an index of
prognosis and as a guide in the design of antiproteolytic
strategies aimed at controlling the progression of the
disease.
Note Added in Proof—While this manuscript was being
prepared, the new MT-MMP was reported [Will, H. and
Hinzmann, B. (1995) Eur. J. Biochem. 231, 602-608].
Thus, MT-MMP-2 in this paper will be renamed as MT-
MMP-3.
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